Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
Adia Nutrition (OTCQB: ADIA) announced its Form 10 registration statement became effective on February 3, 2026, transitioning the company to full SEC reporting under Section 12(g). As a fully reporting registrant, Adia will file audited Form 10-Ks, quarterly 10-Qs, 8-Ks, and other disclosures.
The company said it is accelerating preparations for a potential NASDAQ Capital Market uplisting, named Dr. Brian Browning lead physician, noted an IRB-approved autism stem cell study now open worldwide, and referenced broad operational expansion in 2025.
Adia Nutrition (OTCQB: ADIA) named Dr. Brian L. Browning as lead physician for all orthopedic treatments and specialties at Adia Med in Winter Park, Florida, effective February 2, 2026.
Dr. Browning is board-certified in family and neuromusculoskeletal medicine, leads non-surgical regenerative care, and will oversee stem cell, PRP, ultrasound-guided injections, and related orthopedic services integrated with Adia Med's AdiaVita products.
Adia Nutrition (OTCQB: ADIA) announced a documentary documenting wrestler Jeff Sciullo's June 2025 tricep injury and recovery using Adia Med's AdiaVita stem cell protocol. Filmed for The Dr. Asa Network, the film highlights doses delivering >100 million umbilical cord stem cells and >3 trillion exosomes per dose and will air February–March 2026 across radio, TV, podcast, and social platforms.
The company invites clinic licensing and strategic partnerships to expand access to its regenerative therapies.
Adia Nutrition (OTCQB: ADIA) announced details of an IRB-approved, 24-month randomized crossover study (NCT07304440) testing umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) in ~100 children age 3-12 with confirmed autism spectrum disorder.
The interventional phase delivers three monthly AdiaVita infusions plus glutathione in the active arm; the comparator arm begins with glutathione alone and may crossover later. Primary outcome is change in ATEC scores with close safety monitoring. A one-time $12,000 participation fee covers both phases and all study activities. Recruitment is active at Adia Med in Winter Park, Florida, open to U.S. and international families who can attend visits.
Adia Nutrition (OTCQB: ADIA) announced that the SEC notified the company its Form 10 will not be subject to further review and will automatically become effective on February 3, 2026 (60 days after the Dec 5, 2025 filing). Upon effectiveness, Adia will transition to full SEC reporting under the Securities Exchange Act of 1934 and begin filing audited annual reports on Form 10-K and quarterly reports on Form 10-Q. The company said this status enhances transparency for investors and supports its plans to scale stem cell therapies, expand clinics and labs, and advance clinical studies. Effectiveness does not guarantee immediate listing on a national exchange but positions Adia to pursue eligibility requirements.
Adia Nutrition (OTCQB: ADIA) announced that Emmanuela Derisbrun, APRN, FNP-C, has moved from subcontractor to employed provider at Adia Med to support rising patient volume and the launch of an IRB-approved autism spectrum disorder regenerative study (NCT07304440). Emmanuela has administered stem cell treatments and therapeutic plasma exchange (TPE) at Adia Med and brings experience in IV vitamin therapies, hormone replacement, thyroid disorders, hypertension, diabetes, sickle cell disease, post-COVID care, and chronic pain management. The company said the hire strengthens clinical capacity as patient demand grows and the autism study begins; contact and study details are provided on ClinicalTrials.gov and Adia Med's website.
Adia Nutrition (OTCQB: ADIA) subsidiary Adia Med of Winter Park has begun recruiting for a 24-month randomized interventional study (NCT07304440) testing AdiaVita—an umbilical cord blood-derived stem cell and exosome product—combined with glutathione versus glutathione alone in ~100 children ages 3–12 with confirmed autism spectrum disorder. Primary outcome is change in total ATEC score at six months; safety, tolerability and quality of life will be tracked. The initial three-month phase includes a crossover option and participation requires a one-time fee of $12,000.
ADIA Nutrition (OTCQB: ADIA) announced the appointment of Dawn Bell as Chief Revenue Officer at its ADIA Labs subsidiary on January 8, 2026. Bell brings more than 15 years of sales strategy experience in medical device and pharmaceutical sectors and will lead revenue growth efforts and physician/clinic partnerships to integrate ADIA's regenerative therapies and diagnostic services.
The appointment coincides with ADIA's nationwide clinic expansion momentum and the planned launch of its first IRB-approved clinical study on autism at Adia Med of Winter Park, reflecting a push to advance clinical and commercial initiatives.
Adia Nutrition (OTCQB: ADIA) announced a patent-pending, randomized interventional clinical study for Autism Spectrum Disorder (NCT07304440) is now live on ClinicalTrials.gov. The trial plans to enroll approximately 100 children aged 3–12, comparing intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) versus glutathione alone.
Primary outcomes use ATEC scores to assess speech, sociability, sensory awareness, and behavior; the study includes a 24-month follow-up. Recruitment is expected to begin in January 2026 after independent IRB approval in December 2025.
Adia Nutrition (OTCQB: ADIA) recapped 2025 operational and financial milestones that management says position the company for scalable growth and a Nasdaq uplisting pathway.
Key disclosed achievements include revenue surges >200% quarter-over-quarter in preliminary Q3 results, profit margins exceeding 20%, a tripled sales force with four regional divisions, preferred-vendor access to over 4,000 personal injury physicians, divestiture of a non-core coffee subsidiary while retaining an 18% equity stake, advanced payer negotiations, and filing a Form 10 with expected approval in early 2026.
FAQ
What is the current stock price of Adia Nutrition (ADIA)?
What is the market cap of Adia Nutrition (ADIA)?
